IsoPlexis Closes $5.4 Million

According to a recent SEC filing, software startup IsoPlexis has raised $5.4 million in financing from an undisclosed investor.

IsoPlexis is a life sciences company that is developing a cellular response analysis platform that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development and informing physician decisions. IsoPlexis is headquartered in Branford, CT.